GMC gets breakthrough drug against breast cancer
Becomes first govt hospital in country to introduce Rs 4.20 lakh worth injection
Panaji: Injecting a breakthrough addition to breast cancer treatment, the Goa Medical College (GMC) on Sunday became the first government hospital in the country to administer `4.20 lakh worth Pertuzumab-Trastuzumab fixed drug combination injection to a patient.
The drug represents a significant advancement in cancer care. It is administered subcutaneously in the thigh, offering a streamlined alternative to the conventional hour-long intravenous drip.
This approach not only enhances patient comfort but also ensures a more efficient delivery of the therapeutic agents.
Expressing his happiness over the novel addition to breast cancer treatment protocol, Health Minister Vishwajit Rane said, “We are proud to announce the introduction of the Pertuzumab-Trastuzumab fixed drug combination at the Goa Medical College, marking a significant breakthrough in breast cancer treatment. This innovative approach, administered subcutaneously, not only enhances patient comfort but exemplifies GMC’s commitment to advancing cancer care.”
Stating that the government wants to ensure free healthcare to all, Rane said, “We have also tied up with Tata Memorial Centre to make sure that people receive the best treatment
for cancer. This World Cancer Day, we reaffirm our dedication to improving the lives of those affected by breast cancer and staying at the forefront of medical advancements.”
A full-fledged cancer hospital, for which the government has tied up with the Tata Memorial Centre, will come in the next 16 months.
“There have been variations in design as specified by the Tata Memorial Centre because we have signed a memorandum of understanding with it,” he said.
The GMC has been providing comprehensive care to breast cancer patients, employing the antibody Trastuzumab in conjunction with chemotherapy.
Recognising the evolving landscape of cancer therapeutics, the medical community at the GMC has now incorporated Pertuzumab, a second antibody, into the treatment regimen.
Commencing from February 4 (World Cancer Day), the GMC will make the drug available to those diagnosed with breast cancer before they undergo surgery.
Head of department of oncology at the GMC Dr Anupama Borkar expressed her optimism about the positive impact of the new treatment modality.
“We believe that the Pertuzumab-Trastuzumab fixed drug combination will not only contribute to the efficacy of breast cancer treatment but also simplify the therapeutic process for our patients. The subcutaneous administration reduces the treatment duration and offers a more patient-friendly experience,” Dr Borkar said.
